Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biohaven (NYSE: BHVN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman and Chief Executive Officer, Vlad Coric, M.D., is scheduled to deliver a presentation at The Westin St. Francis Hotel in San Francisco, California. The presentation will take place on Monday, January 13, 2025, at 8:15 am Pacific Time.
Biohaven (NYSE: BHVN) ha annunciato la sua partecipazione alla 43ª Conferenza annuale J.P. Morgan Healthcare. Il Presidente e Amministratore Delegato della società, Vlad Coric, M.D., è programmato per tenere una presentazione presso il The Westin St. Francis Hotel di San Francisco, California. La presentazione si svolgerà lunedì 13 gennaio 2025, alle 8:15 ora del Pacifico.
Biohaven (NYSE: BHVN) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El Presidente y Director Ejecutivo de la compañía, Vlad Coric, M.D., está programado para realizar una presentación en el The Westin St. Francis Hotel en San Francisco, California. La presentación tendrá lugar el lunes 13 de enero de 2025, a las 8:15 a.m. Hora del Pacífico.
Biohaven (NYSE: BHVN)는 제43회 JP 모건 헬스케어 컨퍼런스에 참여할 것을 발표했습니다. 회사의 회장 겸 CEO인 Vlad Coric, M.D.가 캘리포니아 샌프란시스코의 The Westin St. Francis Hotel에서 발표를 할 예정입니다. 발표는 2025년 1월 13일 월요일 오전 8:15 태평양 표준시에 진행될 예정입니다.
Biohaven (NYSE: BHVN) a annoncé sa participation à la 43e Conférence annuelle J.P. Morgan Healthcare. Le président et PDG de l'entreprise, Vlad Coric, M.D., est prévu pour faire une présentation au The Westin St. Francis Hotel à San Francisco, Californie. La présentation aura lieu le lundi 13 janvier 2025 à 8h15, heure du Pacifique.
Biohaven (NYSE: BHVN) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Der Vorsitzende und CEO des Unternehmens, Vlad Coric, M.D., wird eine Präsentation im The Westin St. Francis Hotel in San Francisco, Kalifornien, halten. Die Präsentation findet am Montag, den 13. Januar 2025, um 8:15 Uhr pazifischer Zeit statt.
- None.
- None.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit www.biohaven.com.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345039.html
SOURCE Biohaven Ltd.
FAQ
When is Biohaven (BHVN) presenting at the 2025 J.P. Morgan Healthcare Conference?
Where will the BHVN presentation at the J.P. Morgan Healthcare Conference take place?
Who will represent BHVN at the 2025 J.P. Morgan Healthcare Conference?